Literature DB >> 19555384

The impact of lymph node yield on Duke's B and C colorectal cancer survival.

V L Fretwell1, C W Ang, E M Tweedle, P S Rooney.   

Abstract

AIM: The number of positive lymph nodes retrieved following colorectal cancer (CRC) resection impacts on the staging and further treatment of the disease. We compared 5-year survival by lymph node yield for Duke's B and C patients to assess the impact on prognosis.
METHOD: A retrospective methodology was employed to review patients who underwent operative resection for Duke's B or C CRC between 1999 and 2003.
RESULTS: A total of 351 patients were included in our analyses. Lymph node yield, N-stage and extramural vascular invasion were independent predictors of overall 5-year survival. A significant difference in 5-year survival by lymph node yield was seen among Duke's B patients (< 9 nodes vs ≥ 9 nodes, 45.2%vs 68.4%; P = 0.0043) and Duke's C patients (< 10 nodes vs ≥ 10 nodes, 25.6%vs 48.8%; P = 0.0099). There was a significant reduction in the relative risk of 2.8% in mortality for each additional node sampled in Duke's B and C patients (RR 0.972, 95% confidence interval 0.949-0.994, P = 0.0102). Duke's B patients who had < 9 lymph node yield and no neoadjuvant/adjuvant treatment had a similar survival to all Duke's C patients (47.8%vs 41.7%, P = 0.5136).
CONCLUSION: Lymph node yield independently predicts for survival in patients with Duke's B and C CRC. Duke's B patients with < 9 lymph node yield have no better survival than patients with Duke's C disease. Therefore, prospective randomized studies are required to examine if inadequate lymph node yield could be one of the deciding factors in offering adjuvant therapy among Duke's B cancer patients.
© 2010 The Authors. Colorectal Disease © 2010 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Mesh:

Year:  2010        PMID: 19555384     DOI: 10.1111/j.1463-1318.2009.01966.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  3 in total

1.  Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients.

Authors:  Muriel X G Draht; Kim M Smits; Benjamin Tournier; Valerie Jooste; Caroline Chapusot; Beatriz Carvalho; Arjen H G Cleven; Sarah Derks; Kim A D Wouters; Eric J T Belt; Hein B A C Stockmann; Herman Bril; Matty P Weijenberg; Piet A van den Brandt; Adriaan P de Bruïne; James G Herman; Gerrit A Meijer; Françoise Piard; Veerle Melotte; Manon van Engeland
Journal:  Mol Oncol       Date:  2014-02-02       Impact factor: 6.603

Review 2.  Stage migration vs immunology: The lymph node count story in colon cancer.

Authors:  Bruno Märkl
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

3.  Impact of Inadequate Number of Lymph Nodes Examined on Survival in Stage II Colon Cancer.

Authors:  Qi Wu; Zhiyuan Zhang; Yijiao Chen; Jiang Chang; Yudong Jiang; Dexiang Zhu; Ye Wei
Journal:  Front Oncol       Date:  2021-09-20       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.